Johnson & Johnson buys Intra-Cellular Therapies for $14.6 billion
MLex Summary: Johnson & Johnson has agreed to buy drugmaker Intra-Cellular Therapies for $14.6 billion. The closing of the transaction is expected to occur later this year subject to applicable regulatory...To view the full article, register now.
Already a subscriber? Click here to view full article